度普利尤单抗在哮喘患者中的疗效及对血清和痰液TLR、NF-κB表达的影响研究  

Study on the Effect of Dupilumab in the Patients with Asthma and Influence for the Expression of Serum and Sputum TLR and NF-κB

作　　者：吴燕玲 叶晓艺[1] 蔡志明[1] WU Yanling;YE Xiaoyi;CAI Zhiming(Department of Respiratory and Critical Care Medicine,First Hospital of Quanzhou City,Quanzhou,Fujian 362000,China)

机构地区：[1]泉州市第一医院呼吸与危重症医学科,福建泉州362000

出　　处：《中国医药指南》2025年第9期38-41,共4页Guide of China Medicine

摘　　要：目的探究度普利尤单抗在哮喘患者中的疗效及对血清和痰液Toll样受体(TLR)、核因子-κB(NF-κB)表达的影响。方法将2022年10月至2023年9月泉州市第一医院收治的80例哮喘患者按照随机数字表法分为两组。对照组(n=40)进行常规哮喘治疗,观察组(n=40)则采用度普利尤单抗治疗。比较两组的哮喘治疗总有效率、不良反应发生率、治疗前后的疾病指标[嗜酸性粒细胞(EOS)、免疫球蛋白E(IgE)及呼出气一氧化氮(FeNO)]、血清和痰液TLR[Toll样受体-2(TLR-2)及Toll样受体-4(TLR-4)]、NF-κB。结果观察组的哮喘治疗总有效率显著高于对照组(P<0.05),两组的三类不良反应发生率比较,差异无统计学意义(P>0.05),治疗前两组的疾病指标、血清和痰液TLR、NF-κB比较,差异无统计学意义(P>0.05),治疗后观察组的疾病指标、血清和痰液TLR、NF-κB均显著低于对照组,且两组治疗后的疾病指标、血清和痰液TLR、NF-κB均显著低于组内治疗前(P<0.05)。结论度普利尤单抗在哮喘患者中的疗效较好,安全性较高,且可有效控制患者的血清和痰液TLR、NF-κB的表达,因此在哮喘患者中的应用价值相对较高。Objective To investigate the effect of Dupilumab in the patients with asthma and influence for the expression of serum and sputum toll-like receptor(TLR)and nuclear factor kappa-B(NF-κB).Methods A total of 80 patients with asthma from October 2022 to September 2023 were divided into two groups by the random number table.The control group(n=40)were treated with conventional treatment for asthma,the observation group(n=40)were treated with dupilumab.Then the total effective rates for asthma,adverse reaction rates,disease indexes[eosinophilia(EOS),immunoglobulin E(IgE)and fractional exhaled nitric oxide(FeNO)],serum and sputum TLR[toll-like receptor-2(TLR-2)and toll-like receptor-4(TLR-4)]and NF-κB before and after the treatment of two groups were compared.Results The total effective rate for asthma of observation group was significantly higher than that of control group(P<0.05).Three kinds of adverse reaction rates of two groups were compared,the differences were not statistically significant(P>0.05).The disease indexes,serum and sputum TLR and NF-κB of two groups before the treatment were compared,the differences were not statistically significant(P>0.05).The disease indexes,serum and sputum TLR and NF-κB of observation group after the treatment were significantly lower of those of control group,the disease indexes,serum and sputum TLR and NF-κB of two groups after the treatment were significantly lower than those within group before the treatment(P<0.05).Conclusions The effect of Dupilumab in the patients with asthma is better,its safety is high too,and it can effectively control the the expression of serum and sputum TLR and NF-κB of patients,so its application value in the patients with asthma is relatively higher.

关 键 词：度普利尤单抗 哮喘 疗效 血清 痰液 Toll样受体 核因子-κB 

分 类 号：R562.25[医药卫生—呼吸系统]